Published in Cancer Res on June 01, 1999
Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer (2008) 1.52
Supplement use and risk of cutaneous squamous cell carcinoma. J Am Acad Dermatol (2011) 1.52
Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res (2009) 1.24
CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res (2010) 1.23
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology (2009) 1.19
Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev (2008) 1.14
Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene (2005) 1.12
Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol (2002) 1.05
CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology (2010) 1.04
Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology (2012) 1.00
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene (2013) 0.97
1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther (2008) 0.96
Vitamin D deficiency and the lung: disease initiator or disease modifier? Nutrients (2013) 0.90
Vitamin D intake and lung cancer risk in the Women's Health Initiative. Am J Clin Nutr (2013) 0.89
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.89
Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 0.88
Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle (2013) 0.88
Vitamin D in cutaneous carcinogenesis: part II. J Am Acad Dermatol (2012) 0.86
Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol. Cancer (2012) 0.85
Epigenetic silencing of CYP24 in the tumor microenvironment. J Steroid Biochem Mol Biol (2010) 0.84
Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo. Horm Cancer (2011) 0.84
Mechanistic Effects of Calcitriol in Cancer Biology. Nutrients (2015) 0.82
Genome-wide approaches for identification of nuclear receptor target genes. Nucl Recept Signal (2006) 0.79
Estimated intake of vitamin D and its interaction with vitamin A on lung cancer risk among smokers. Int J Cancer (2014) 0.78
Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World J Urol (2005) 0.78
Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma. J Thorac Oncol (2014) 0.76
Vitamin D3 signalling in the brain enhances the function of phosphoprotein enriched in astrocytes--15 kD (PEA-15). J Cell Mol Med (2009) 0.76
Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer. Cancer Prev Res (Phila) (2015) 0.76
Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis. PPAR Res (2016) 0.75
1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p. Oncotarget (2017) 0.75
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits. Neurology (2009) 2.46
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst (1994) 2.05
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res (1988) 1.84
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Metastatic carcinoma involving the testis. Clinical and pathologic distinction from primary testicular neoplasms. Cancer (1984) 1.71
Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol (2004) 1.70
Cutaneous involvement in malignant histiocytosis. Case report and review of the literature. Arch Dermatol (1981) 1.64
Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol (1993) 1.50
Clinical features and natural history of intramedullary spinal cord metastasis. Cancer (1985) 1.43
Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin Cancer Res (2000) 1.40
Transient stress lymphocytosis during crisis of sickle cell anemia and emergency trauma and medical conditions. An immunophenotyping study. Arch Pathol Lab Med (1990) 1.39
Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res (2001) 1.35
Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood (1991) 1.35
Behavior problems in children at time of first recognized seizure and changes over the following 3 years. Epilepsy Behav (2011) 1.27
Photon correlation spectroscopy of hemoglobin: diffusion of oxy-HbA and oxy-HbS. Biopolymers (1978) 1.25
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology (1997) 1.24
Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res (1997) 1.20
Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol (1997) 1.20
Formation and alignment of Z lines in living chick myotubes microinjected with rhodamine-labeled alpha-actinin. J Cell Biol (1986) 1.19
Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem (2001) 1.19
Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol (1993) 1.18
High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol (1992) 1.15
Modulation of angiotensin II-induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole. J Clin Invest (1991) 1.15
Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res (2001) 1.15
Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism (2001) 1.15
Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep (1985) 1.15
Acquired extrinsic pulmonic stenosis caused by mediastinal tumors. Cancer (1982) 1.13
A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res (1999) 1.12
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res (2000) 1.11
Pregelation aggregation of sickle cell hemoglobin. Proc Natl Acad Sci U S A (1974) 1.11
Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res (2001) 1.09
Myocardial infarction in sickle cell disease. J Natl Med Assoc (1996) 1.08
Sickle cell anemia: does myocardial ischemia occur during crisis? J Natl Med Assoc (1991) 1.07
Factors influencing options in primary breast cancer treatment. J Clin Oncol (1987) 1.07
Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol (1992) 1.05
A phase II study of taxol in patients with malignant melanoma. Invest New Drugs (1991) 1.04
Mechanical properties of oxygenated red blood cells in sickle cell (HbSS) disease. Blood (1984) 1.04
Bromide intoxication. Johns Hopkins Med J (1976) 1.04
Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci (1986) 1.03
Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. Am J Clin Nutr (1997) 1.03
Perceived social support among depressed elderly, middle-aged, and young-adult samples: cross-sectional and longitudinal analyses. J Affect Disord (1999) 1.02
The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. J Clin Endocrinol Metab (1982) 1.01
Liver involvement in sickle cell disease. Medicine (Baltimore) (1985) 1.00
Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am (1992) 1.00
Bone regeneration within a human segmental mandible defect: a preliminary report. Am J Otolaryngol (1995) 1.00
Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol (2011) 0.99
A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg (1997) 0.98
Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol (2001) 0.98
Identification of eleven human hemoglobin variants by high-performance liquid chromatography: additional data on functional properties and clinical expression. Biochem Genet (1982) 0.98
Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst (1998) 0.97
Spinal cord compression in prostate cancer. J Neurooncol (1995) 0.97
Arterial blood pressure in adults with sickle cell disease. Arch Intern Med (1981) 0.97
Academic problems in children with seizures: relationships with neuropsychological functioning and family variables during the 3 years after onset. Epilepsy Behav (2010) 0.96
Effect of polymerization tendency on haematological, rheological and clinical parameters in sickle cell anaemia. Br J Haematol (1989) 0.96
A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol (2000) 0.95
Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med (1982) 0.95
Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemother Pharmacol (1992) 0.94
Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement. Cancer (1982) 0.94
Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors. Cancer Res (1988) 0.94
Catalysis of the disproportionation of superoxide by metalloporphyrins. III. J Inorg Biochem (1981) 0.94
Racial patterns in pernicious anemia. Early age at onset and increased frequency of intrinsic-factor antibody in black women. N Engl J Med (1978) 0.93
Effects of Host Resistance and Temperature on Development of Globodera tabacum solanacearum. J Nematol (2001) 0.93
Metastatic Leydig cell tumor of the testis. Report of three cases and review of the literature. Cancer (1986) 0.93
'Sarcoidosis' and sarcoid-like lesions. Their occurrence after cytotoxic and radiation therapy of testis cancer. Arch Intern Med (1981) 0.93
Lecithin inverse microemulsions for the pulmonary delivery of polar compounds utilizing dimethylether and propane as propellants. Pharm Dev Technol (2000) 0.93
Age and growth factors in porcine full-thickness wound healing. Wound Repair Regen (2002) 0.93
Endothelium-derived relaxing factor modulates endothelin action in afferent arterioles. Hypertension (1991) 0.92
Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res (1994) 0.92
Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease. Clin Sci (Lond) (1989) 0.92
Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. Biochem Pharmacol (1996) 0.91
Rheology of the sickle cell disorders. Baillieres Clin Haematol (1987) 0.91
Influence of oxygen tension on the viscoelastic behavior of red blood cells in sickle cell disease. Blood (1986) 0.90
Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol (1996) 0.90
Managing Root-knot on Tobacco in the Southeastern United States. J Nematol (1989) 0.90
Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep (1987) 0.89
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res (1996) 0.89
Gynecomastia in men following antineoplastic therapy. Arch Intern Med (1982) 0.88
Serious hyponatremia in patients with cancer: management with demeclocycline. Cancer (1981) 0.88
Unsuspected pernicious anemia in a patient with sickle cell disease receiving routine folate supplementation. Arch Intern Med (1987) 0.88
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol (2011) 0.88
Electrocardiogram analysis in adult patients with sickle cell disease. J Natl Med Assoc (1987) 0.88
Relation between absolute thresholdand duration-of-tone pulses in the bottlenosed porpoise. J Acoust Soc Am (1968) 0.88
Important clinical pharmacologic considerations in the use of methadone in cancer patients. Cancer Treat Rep (1979) 0.88
Rheologic impairment of sickle RBCs induced by repetitive cycles of deoxygenation-reoxygenation. Blood (1988) 0.87
alpha-Thalassemia: prevalence and hematologic findings in American Blacks. Arch Intern Med (1982) 0.87